Reports across outlets say a large study finds that people with type 2 diabetes who stop taking GLP-1 weight-loss drugs face higher risks than those who continue. The accounts describe findings that include increased risk of heart attack and stroke, as well as higher likelihood of early death.
The Independent frames the issue specifically around potential harm to people with type 2 diabetes, warning that stopping the injections “may” increase death risk. The Daily Mail and Mail Online emphasise the scale of the risk figures, highlighting claims about “double” the cardiovascular risk and a much higher risk of dying early, presenting the conclusion as applying even if weight is maintained.
While the outlets share the same core claim—that discontinuing GLP-1s is associated with worse outcomes—their emphases differ between a cautious wording focused on diabetes mortality (The Independent) and more attention to prominent numerical comparisons (Daily Mail, Mail Online).
